SCYNEXIS, Inc. Receives Four Grants Under Federal Therapeutic Discovery Project Program

11/11/2010 11:13:23 AM

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Drug discovery and development company SCYNEXIS, Inc. today announced that the Company has been awarded four grants totaling $977,917 under the U.S. Federal Government’s Qualifying Therapeutic Discovery Project (QTDP). SCYNEXIS is developing a proprietary internal pipeline of cyclophilin inhibitors, a class of drugs that hold significant potential for the treatment of a broad range of diseases. The Company’s lead candidate from the platform, SCY-635, is currently in clinical trials for the treatment of hepatitis C virus (HCV). The grant applications are related to the development of four of the Company’s cyclophilin inhibitor programs:

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• SCYNEXIS, Inc.

• Biotech/Pharma - Grants